Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: A sequential dose escalation pilot study

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 1, 2010, Pages 50-57

  Miralbell, Raymond ^a,b   Moll, Meritxell ^a   Rouzaud, Michel ^b   Hidalgo, Alberto ^c   Toscas, José Ignacio ^a   Lozano, Joan ^a   Sanz, Sergi ^d   Ares, Carmen ^b   Jorcano, Sandra ^a   Linero, Dolors ^a   Escudé, Lluís ^a  

^a Institut Oncològic Teknon   (Spain)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c CENTRO MÉDICO TEKNON   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Extracranial stereotactic radiotherapy; Intensity modulated radiotherapy; Prostate cancer; Radiation toxicity

Indexed keywords

ANDROGEN DEPRIVATION; DISEASE FREE SURVIVAL; DISEASE-SPECIFIC SURVIVALS; DOSE ESCALATION; EXTERNAL RADIOTHERAPY; GASTROINTESTINAL TOXICITIES; HIGH DOSE; HIGH-DOSE RATE BRACHYTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; INTERNAL ORGANS; LOW DOSE; PELVIC IRRADIATION; PILOT STUDIES; PROSTATE CANCERS; PROSTATE VOLUME; RADIATION THERAPY; RADIATION TOXICITY; SCORING SYSTEMS; STEREOTACTIC RADIOTHERAPY; TOTAL DOSE;

DISEASES; ONCOLOGY; RADIATION DAMAGE; TOXICITY; TUMORS;

RADIOTHERAPY;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; URINARY TRACT INJURY;

AGED; ANDROGEN ANTAGONISTS; FEASIBILITY STUDIES; GASTROINTESTINAL TRACT; HUMANS; IMMOBILIZATION; MALE; PILOT PROJECTS; PROSTATE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TUMOR BURDEN; URINARY BLADDER;

EID: 77955863475     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1689     Document Type: Article

References (38)

1. G.E. Hanks, K.L. Martz, and J.J. Diamond The effect of dose on local control of prostate cancer Int J Radiat Oncol Biol Phys 15 1988 1299 1306
2. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
3. F.A. Vicini, A. Abner, and K.L. Baglan Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better? Int J Radiat Oncol Biol Phys 51 2001 1200 1208
4. J.B. Fiveash, G. Hanks, and M. Roach 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review Int J Radiat Oncol Biol Phys 47 2000 335 342
5. G.E. Hanks, A.L. Hanlon, B. Epstein, and E.M. Horwitz Dose response in prostate cancer with 8-12 years' follow-up Int J Radiat Oncol Biol Phys 54 2002 427 435
6. P. Kupelian, D. Kuban, and H. Thames Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995 Int J Radiat Oncol Biol Phys 61 2005 415 419
7. J.R. Sathya, I.R. Davis, and J.A. Julian Randomized trial comparing Iridium implants plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate J Clin Oncol 23 2005 1192 1199
8. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M.D. Anderson Phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
9. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. A randomized controlled trial J Am Med Assoc 294 2005 1233 1239
10. M.L. Zelefsky, Z. Fuks, and M. Hunt High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116
11. P.A. Kupelian, T.R. Willoughby, and C.H. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience J Clin Oncol 68 2007 1424 1430
12. L. strom, D. Pedersen, and C. Mercke Long-term outcome of high-dose rate brachytherapy in radiotherapy of localised prostate cancer Radiother Oncol 74 2005 151 157
13. D.J. Demanes, R.R. Rodriguez, and L. Schour High-dose rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results Int J Radiat Oncol Biol Phys 61 2005 1306 1316
14. G.M. Duchesne, S.G. Williams, R. Das, and K.H. Tai Patterns of toxicity following high-dose rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results Radiother Oncol 84 2007 128 134
15. R.M. Galalae, G. Kovács, and J. Schultze Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer Int J Radiat Oncol Biol Phys 52 2002 81 90
16. P.J. Hoskin, K. Motohashi, and P. Bownes High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial Radiother Oncol 84 2007 114 120
17. T. Martin, S. Roddiger, and R. Kurek 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer Radiother Oncol 71 2004 35 41
18. D.J. Brenner, A.A. Martinez, and G.K. Edmundson Direct evidence that prostate tumors show high sensitivity to fractionation (low alfa/beta ratio) similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
19. D.J. Brenner Hypofractionation for prostate cancer radiotherapy - what are the issues Int J Radiat Oncol Biol Phys 57 2003 912 914
20. J.P. Logue, and J.H. Hendry Hypofractionation for prostate cancer Int J Radiat Oncol Biol Phys 49 2001 152
21. M.E. Cheng, D.A. Johnston, and K. Tang Detailed mapping of prostate carcinoma foci: Biopsy strategy implications Cancer 89 2000 1800 1809
22. C. Parker, P. Warde, and C. Catton Salvage radiotherapy for PSA failure after radical prostatectomy Radiother Oncol 61 2001 107 116
23. C. Ares, Y. Popowski, and S. Pampallona Hypofractionated boost with high-dose rate brachytherapy and open MRI-guided implants for locally aggressive prostate cancer: A sequential dose escalation pilot study Int J Radiat Oncol Biol Phys 2009 Feb 26 [Epub ahead of print]
24. M. Roach, C. Marquez, and H.-S. Yuo Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1993 33 37
25. S. Bieri, R. Miralbell, and P. Nouet Reproducibility of conformal radiation therapy in localized carcinoma of the prostate without rigid immobilization Radiother Oncol 38 1996 223 230
26. G. Soete, D. Verellen, and D. Michielsen Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 54 2002 948 952
27. R. Miralbell, M. Moll, and R. Arnalte Target repositioning optimization in prostate cancer: Is intensity modulation radiotherapy under stereotactic conditions feasible? Int J Radiat Oncol Biol Phys 59 2004 366 371
28. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer J Am Med Assoc 280 1998 969 974 (Pubitemid 28445094)
29. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
30. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
31. E.L. Kaplan, and P. Meier Nonparametric Estimation from Incomplete Observations J Am Stat Assoc 53 1958 457 481
32. D. Kuban, A. Pollack, and E. Huang Hazards of dose escalation in prostate cancer radiotherapy Int J Radiat Oncol Biol Phys 57 2003 1260 1268
33. D.P. Dearnaley, E. Hall, and D. Lawrence Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects British Journal of Cancer 92 2005 488 498
34. H.-U. Kauczor, C. Zechmann, B. Stieltjes, and M.-A. Weber Functional magnetic resonance imaging for definig the biological target volume Cancer Imaging 6 2006 51 55
35. T. Hara, N. Kosaka, and H. Kishi PET imaging of prostate cancer using carbon-11 choline J Nucl Med 39 1998 990 995
36. 11C Acetate PET Imaging of Prostate Cancer J Nucl Med 43 2002 181 186
37. D.T. Price, E. Coleman, and R.P. Liao Comparison of 18F Fluorocholine and 18F Fluorodeoxyglucose for positron emission tomography of androgen dependents and androgen independent prostate cancer J Urol 168 2002 273 280
38. N.Y. Lee, J.G. Mechalakos, and S. Nehmeh Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study Int J Radiat Oncol Biol Phys 70 2008 2 13